Charlotte Levin Tykjär Jörgensen (Former)
1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Pam50 intrinsic subtype profiles in primary and metastatic breast cancer show a significant shift toward more aggressive subtypes with prognostic implications
(
- Contribution to journal › Article
- 2020
-
Mark
Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
(
- Contribution to journal › Article
-
Mark
Evolution of estrogen receptor status from primary tumors to metastasis and serially collected circulating tumor cells
(
- Contribution to journal › Article
-
Mark
Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression
(
- Contribution to journal › Article
-
Mark
The distribution of circulating tumor cells is different in metastatic lobular compared to ductal carcinoma of the breast –long term prognostic significant
(
- Contribution to journal › Article
- 2018
-
Mark
Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial
(
- Contribution to journal › Article
- 2017
-
Mark
High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial
(
- Contribution to journal › Article
- 2014
-
Mark
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
(
- Contribution to journal › Article
-
Mark
PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients
(
- Contribution to journal › Article
- 2013
-
Mark
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
(
- Contribution to journal › Article